Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today

By Maxx Chatsko - Updated May 9, 2019 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharma company announced first-quarter 2019 operating results.

What happened

Shares of Flexion Therapeutics (FLXN) rose more than 18% today after the company announced first-quarter 2019 operating results. The business actually missed Wall Street estimates for revenue and loss per share, but analysts were pleased with progress in ramping up sales of the company's sole drug product.

Zilretta, an injection for management of osteoarthritis knee pain, generated revenue of $10.6 million in Q1 2019. That lagged just behind analyst estimates of $11 million, according to numbers compiled by Yahoo! Finance. But Flexion Therapeutics disclosed preliminary April sales of $5.1 million. That one-month total suggests a promising acceleration and puts the drug on pace to top analyst expectations for Q2 2019 revenue of $14.7 million.

As of 11:42 a.m. EDT, the stock had settled to a 14% gain.

A pair of hands holding up piles of coins.

Image source: Getty Images.

So what

Flexion Therapeutics had a difficult 2018. Shares fell 54.8% as the business struggled with a slow market launch for Zilretta compounded by issues with insurance reimbursement. Recent sales data provide hope that the drug is finally gaining market traction.

Management remains confident that the woes of last year are firmly behind the business. It reaffirmed full-year 2019 guidance for Zilretta revenue of $65 million to $80 million. That suggests a significant sales surge is on the way.

Now what

The operational performance in Q1 2019 is encouraging. The business delivered nearly $9 million in gross profit, which offset an equal increase in operating expenses. While Flexion Therapeutics is still generating significant operating losses, it had more than $217 million in available capital at the end of March. Therefore, successfully ramping up sales of Zilretta could begin to nudge the business toward profitability before cash runs out. Now the company just has to execute.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Flexion Therapeutics, Inc. Stock Quote
Flexion Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.